News

The open-label extension RIDE and RISE phase III studies of ranibizumab (Lucentis, Genentech) indicated that the beneficial results of the drug for treating diabetic macular edema were maintained over the long-term with less than monthly follow-up or injection treatment.

The first results from a phase I trial of gene therapy for exudative age-related macular degeneration using a subretinal injection suggest that the treatment is safe and well tolerated even in the elderly population and may eliminate the need for frequent reinjection with anti-vascular endothelial growth factor agents.

Nicox S.A. has signed an agreement to acquire all of the outstanding equity of Aciex Therapeutics, a private, U.S.-based, ophthalmic development pharmaceutical company with a pipeline of therapeutics addressing the ophthalmic market, including allergy and inflammation.

Ohr Pharmaceutical has announced positive top-line interim results for its double-masked, placebo-controlled phase II clinical trial of Squalamine eye drops in patients with wet age-related macular degeneration (AMD).

Aerie Pharmaceuticals has reported successful results for a phase IIb trial for its IOP-lowering therapy-once-daily, quadruple-action Roclatan, a combination of Aerie’s triple-action Rhopressa with latanoprost.

Alimera Sciences' sustained-release intravitreal implant (Iluvien)-its treatment of chronic macular edema-has received a positive outcome of the Repeat-Use Procedure with the Medicines and Healthcare products Regulatory Agency of the United Kingdom serving as the Reference Member State.

A healthy, stable tear film is essential for high quality visual function and stable interblink vision. If patients have dry eye disease, it must be successfully resolved before corneal refractive surgery takes place. Similarly, patients who do not have preoperative dry eye but are at high risk of developing the disease postoperatively also need special attention.

The 1-year results of the inject-and-extend Lucentis Compared to Avastin Study (Lucas) for exudative age-related macular degeneration (AMD) indicated that the two drugs have equivalent effectiveness, said Karina Berg, MD.

The FDA has issued a marketing clearance for Bausch + Lomb’s presbyopia treatment, Biotrue ONEday (nesofilcon A) soft (hydrophilic) daily disposable multifocal contact lenses.

The FDA has approved Allergan’s dexamethasone intravitreal implant (Ozurdex), as a treatment option for diabetic macular edema (DME) in adult patients who have an artificial lens implant or who are scheduled for cataract surgery.

The Federal Trade Commission (FTC) is requiring Akorn Enterprises’ subsidiary Hi-Tech Pharmacal to sell the marketing rights for five generic drugs to Watson Laboratories to settle federal charges that Akorn’s acquisition of Hi-Tech was anticompetitive.

Analyses of refractive prediction error in a study including 262 eyes implanted with a variety of pseudophakic IOLs shows benefit for using intraoperative aberrometry with streaming refractive data (ORA System with VerifEye, WaveTec Vision).

Two patients underwent cataract surgery and implantation of a monofocal IOL with a small aperture corneal inlay (Kamra, AcuFocus) in place. The surgery was uneventful, presented no new technical challenges, and resulted in spectacle-free near, intermediate, and distance vision.

Intraoperative aberrometry readings can be useful in reducing astigmatism when used with either conventional diamond blade limbal relaxing incisions and femtosecond laser arcuate incisions. In a study of 50 eyes, no statistically significant difference was found between two groups of patients in postoperative mean residual astigmatism.

In a randomized study including 65 patients undergoing femtosecond laser-assisted or standard phacoemulsification, there were no significant differences between groups in central corneal thickness or endothelial cell loss at 1 week or 1 month postsurgery.